Skip to content

Optimum dose finding study of 0.75% hyperbaric ropivacaine for unilateral subarachnoid block in lower limb orthopedic surgeries

Dose finding study of 0.75% hyperbaric ropivacaine for unilateral subarachnoid block in lower limb orthopedic surgeries

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045396
Enrollment
102
Registered
2022-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Ropivacaine: 0.75% ropivacaine is used in 3 different doses (1ml, 1.5ml, 2ml) in 3 groups with 34 participants each to determine the ideal dose of unilateral subarachnoid block in lower

Sponsors

Department of Anesthesiology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Body weight - 40-85 kg Height - 150-180 cm ASA 1, 2 Duration of surgery - less than 1 hour

Exclusion criteria

Exclusion criteria: Unwilling for subarachnoid block, skin infection at the site of intrathecal injection, allergy to the study drug, coagulopathy, taking anticoagulant drugs, hypovolemia, fixed cardiac output disease, undetermined neurologic disease, spine deformity

Design outcomes

Primary

MeasureTime frame
To determine the ideal dosage of hyperbaric 0.75% ropivacaine for unilateral subarachnoid block in orthopedic lower limb surgeries by assessing the maximum sensory and motor block o both operative and non operative sides by each individual dosageTimepoint: baseline, 20 minutes after the injection for subarachnoid block, 2 hours after the sbaracoid block

Secondary

MeasureTime frame
hemodynamic effects of the 3 different doses for unilateral subarachnoid blockTimepoint: during the surgery

Countries

India

Contacts

Public ContactDr Suchismita Pal

Diamond Harbour Government Medical College and Hospital

suchiofficial21@gmail.com947459903

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026